APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Sponsor: Apollomics (Australia) Pty. Ltd.
Terminated
Study terminated due to administrative reasons.
Other Hepatocellular Carcinoma trials with similar outcome
Listed as NCT03655613, this PHASE1/PHASE2 trial focuses on Hepatocellular Carcinoma and Renal Cell Carcinoma and remains terminated or withdrawn. Sponsored by Apollomics (Australia) Pty. Ltd., it has been updated 12 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Jul 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2019 — Jul 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Apollomics (Australia) Pty. Ltd.
- Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
- Novotech (Australia) Pty Limited
For direct contact, visit the study record on ClinicalTrials.gov .